Coronavirus cases have dropped sharply in South Korea.

What’s the secret to its success?

By Dennis Normile, SCIENCE MAG Mar. 17, 2020 , 8:00 AM

Europe is now the epicenter of the COVID-19 pandemic. Case counts and deaths are soaring in Italy, Spain, France, and Germany, and many countries have imposed lockdowns and closed borders. Meanwhile, the United States, hampered by a fiasco with delayed and faulty test kits, is just guessing at its COVID-19 burden, though experts believe it is on the same trajectory as countries in Europe.

Amid these dire trends, South Korea has emerged as a sign of hope and a model to emulate. The country of 50 million appears to have greatly slowed its epidemic; it reported only 74 new cases today, down from 909 at its peak on 29 February. And it has done so without locking down entire cities or taking some of the other authoritarian measures that helped China bring its epidemic under control. “South Korea is a democratic republic, we feel a lockdown is not a reasonable choice,” says Kim Woo-Joo, an infectious disease specialist at Korea University. South Korea’s success may hold lessons for other countries—and also a warning: Even after driving case numbers down, the country is braced for a resurgence.

Behind its success so far has been the most expansive and well-organized testing program in the world, combined with extensive efforts to isolate infected people and trace and quarantine their contacts. South Korea has tested more than 270,000 people, which amounts to more than 5200 tests per million inhabitants—more than any other country except tiny Bahrain, according to the Worldometer website. The United States has so far carried out 74 tests per 1 million inhabitants, data from the U.S. Centers for Disease Control and Prevention show.

South Korea’s experience shows that “diagnostic capacity at scale is key to epidemic control,” says Raina MacIntyre, an emerging infectious disease scholar at the University of New South Wales, Sydney. “Contact tracing is also very influential in epidemic control, as is case isolation,” she says.

Yet whether the success will hold is unclear. New case numbers are declining largely because the herculean effort to investigate a massive cluster of more than 5000 cases—60% of the nation’s total—linked to the Shincheonji Church of Jesus, a secretive, messianic megachurch, is winding down. But because of that effort, “We have not looked hard in other parts of Korea,” says Oh Myoung-Don, an infectious disease specialist at Seoul National University.

New clusters are now appearing. Since last week, authorities have reported 129 new infections, most linked to a Seoul call center. “This could be the initiation of community spread,” through Seoul and its surrounding Gyeonggi province, Kim says. The region is home to 23 million people.

Lessons from MERS

South Korea learned the importance of preparedness the hard way. In 2015, a South Korean businessman came down with Middle East respiratory syndrome (MERS) after returning from a visit to three Middle Eastern countries. He was treated at three South Korean health facilities before he was diagnosed with MERS and isolated. By then, he had set off a chain of transmission that infected 186 and killed 36, including many patients hospitalized for other ailments, visitors, and hospital staff. Tracing, testing, and quarantining nearly 17,000 people quashed the outbreak after 2 months. The specter of a runaway epidemic alarmed the nation and dented the economy.

“That experience showed that laboratory testing is essential to control an emerging infectious disease,” Kim says. In addition, Oh says, “The MERS experience certainly helped us to improve hospital infection prevention and control.” So far, there are no reports of infections of COVID-19 among South Korean health care workers, he says.

Legislation enacted since then gave the government authority to collect mobile phone, credit card, and other data from those who test positive to reconstruct their recent whereabouts. That information, stripped of personal identifiers, is shared on social media apps that allow others to determine whether they may have crossed paths with an infected person.

After the novel coronavirus emerged in China, Korea Centers for Disease Control and Prevention (KCDC) raced to develop its tests and cooperated with diagnostic manufacturers to develop commercial test kits. The first test was approved on 7 February, when the country had just a few cases, and distributed to regional health centers. Just 11 days later, a 61-year-old woman, known as “Case 31,” tested positive. She had attended 9 and 16 February services at the Shincheonji megachurch in Daegu, about 240 kilometers southeast of Seoul, already feeling slightly ill. Upward of 500 attendees sit shoulder to shoulder on the floor of the church during 2-hour services, according to local news reports.

The country identified more than 2900 new cases just in the next 12 days, the vast majority Shincheonji members. On 29 February alone, KCDC reported more than 900 new cases, bringing the cumulative total to 3150 and making the outbreak the largest by far outside mainland China. The surge initially overwhelmed testing capabilities and KCDC’s 130 disease detectives couldn’t keep up, Kim says. Contact tracing efforts were concentrated on the Shincheonji cluster, in which 80% of those reporting respiratory symptoms proved positive, compared with only 10% in other clusters.

High-risk patients with underlying illnesses get priority for hospitalization, Chun says. Those with moderate symptoms are sent to repurposed corporate training facilities and spaces provided by public institutions, where they get basic medical support and observation. Those who recover and test negative twice are released. Close contacts and those with minimal symptoms whose family members are free of chronic diseases and who can measure their own temperatures are ordered to self-quarantine for 2 weeks. A local monitoring team calls twice daily to make sure the quarantined stay put and to ask about symptoms. Quarantine violators face up to 3 million won ($2500) fines. If a recent bill becomes law, the fine will go up to 10 million won and as much as a year in jail.

In spite of the efforts, the Daegu-Gyeongbuk region ran out of space for the seriously ill. Four people isolated at home, waiting for hospital beds, were rushed to emergency rooms when their conditions deteriorated, only to die there, according to local media.

Still, the numbers of new cases have dropped the past 2 weeks, aided by voluntary social distancing, both in the Daegu-Gyeongbuk region and nationwide. The government advised people to wear masks, wash their hands, avoid crowds and meetings, work remotely, and to join online religious services instead of going to churches. Those with fevers or respiratory illnesses are urged to stay home and watch their symptoms for 3 to 4 days. “People were shocked by the Shincheonji cluster,” Chun says, which boosted compliance. Less than 1 month after Case 31 emerged, “The cluster is coming under control,” Oh says.

Yet new clusters are emerging, and for 20% of confirmed cases, it’s unclear how they became infected, suggesting there is still undetected community spread. “As long as this uncertainty remains, we cannot say that the outbreak has peaked,” Chun says.

More data needed

The government hopes to control new clusters in the same way it confronted the one in Shincheonji. The national testing capacity has reached a staggering 15,000 tests per day. There are 43 drive-through testing stations nationwide, a concept now copied in the United States, Canada, and the United Kingdom. In the first week of March, the Ministry of the Interior also rolled out a smartphone app that can track the quarantined and collect data on symptoms.

Chun Byung-Chul, an epidemiologist at Korea University, says scientists are eager to see more epidemiological data. “We are literally stamping our feet,” Chun says. KCDC releases the basic counts of patients, their age and gender, and how many are linked to clusters. “That is not enough,” Chun says. He and others would like to study detailed individual patient data, which would enable epidemiologists to model the outbreak and determine the number of new infections triggered by each case, also known as the basic reproductive number or R0; the time from infection to the onset of symptoms; and whether early diagnosis improved patients’ outcomes. (South Korea has had 75 deaths so far, an unusually low mortality rate, although the fact that Shincheonji church members are mostly young may have contributed.) Chun says a group of epidemiologists and scientists has proposed partnering with KCDC to gather and share such information, “and we are waiting for their response.”

Kim says medical doctors are also planning to share details of the clinical features of COVID-19 cases in the country in forthcoming publications. “We hope our experience will help other countries control this COVID-19 outbreak.”

With reporting by Ahn Mi-Young in Seoul.

March 18, 2020 | 2 Comments » | 366 views

Subscribe to Israpundit Daily Digest

2 Comments / 2 Comments

  1. ¨China says Japan-developed drug Avigan works against coronavirus
    Positive reception by Chinese government contrasts with reservations in Japan¨

    ¨DALIAN, China/HONG KONG/TOKYO — An influenza medicine developed by a Fujifilm Holdings group company is effective against the new coronavirus, the Chinese government said on Tuesday.

    Beijing has already begun recommending the drug favipiravir, developed by Fujifilm Toyama Chemical and sold under the brand name Avigan.

    “It is very safe and clearly effective,” said Zhang Xinmin, director of the science ministry’s China National Center for Biotechnology Development, in a news conference.

    Fujifilm Toyama developed the drug in 2014. It has been administered to coronavirus patients in Japan since February.

    On Wednesday, shares in Fujifilm shot up 15.4% in Tokyo in the afternoon session. Morning trade in the stock was suspended after a glut of buy orders following Beijing’s announcement.

    Clinical trials were conducted on 200 patients at hospitals in Wuhan and Shenzhen. Results showed that patients who received the drug tested negative in a comparatively short time, while pneumonia symptoms were markedly reduced.

    Patients taking favipiravir tested negative after a median of four days, compared to 11 days in the control group, according to Zhang. There were no clear side effects, he added.

    Another clinical trial in Wuhan revealed that patients treated with favipiravir recovered from fever in 2.5 days on average, versus 4.2 days for other patients. Coughing symptoms also improved within 4.6 days — about 1.4 days earlier than those who did not take the drug.

    Only 8.2% of the patients taking favipiravir needed respiratory aids, whereas 17.1% of the patients in the control group were put on devices.

    The positive reception in China contrasts with reservations over Avigan in Japan, where the drug obtained regulatory approval in 2014 on condition that it would only be used if the government decided to fight new or re-emerging influenza viruses. Studies found that the drug may cause fetal deaths or deformities, and can be transferred in semen.

    South Korea’s ministry of food and drug safety also decided not to import Avigan after infectious disease experts ruled that there was not enough clinical data to prove the drug’s efficacy, the country’s Yonhap news agency reported this week.

    Despite Fujifilm’s surging stock price, it is unclear how the company will benefit if Chinese companies begin to mass produce favipiravir. A Fujifilm spokesperson said the company is not involved in the Chinese clinical trials and is currently evaluating them.

    Fujifilm signed a patent license agreement concerning Favipiravir with China’s Zhejiang Hisun Pharmaceutical in 2016. But the spokesperson said the agreement was canceled last year, although the two parties are still in a “cooperative relationship.”

    The Chinese company said it received official approval to produce the drug in February and can ramp up output of a generic version.

    Fujifilm’s favipiravir patents are valid in Japan, but the substance patent in China expired last year, according to the spokesperson. This clears the way for Zhejiang Hisun to produce the generic version.

    Fujifilm is providing Avigan to Japanese hospitals for clinical research and is also preparing to conduct its own clinical tests in Japan. Research in Japan began in March, with results not expected for several months.

    Shares in Nichi-Iko Pharmaceutical were also up about 15% on Wednesday after the University of Tokyo announced that the company’s Nafamostat drug blocks the coronavirus from entering human cells, effectively inhibiting infections.¨

    ¨Additional reporting by Jada Nagumo.¨

  2. Hungary Announces Successful Isolation of Coronavirus

    China says Japan-developed drug Avigan works against coronavirus
    Positive reception by Chinese government contrasts with reservations in Japan

Leave a Reply

Your email address will not be published.